Favezelimab  (Synonyms: MK-4280; Mavezelimab)

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma^[1]. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

LAG3/CD223

Lymphocyte activation gene-3 (LAG-3) is a cell surface immunomodulatory receptor commonly coexpressed with PD-1 on exhausted T cells and may serve as an escape pathway for lymphoma subjected to PD-1 blockade. Dual blockade of PD-1 and LAG-3 showed synergistic activity in mouse models of colon adenocarcinoma and fibrosarcoma.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3902  [NCBI]

P18627

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.98 kDa

2231068-83-8

Liquid

Colorless to light yellow

[Favezelimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Favezelimab (HY-P99613, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Cancer Res (2019) 79 (13_Supplement): CT106.